mAbxience | News

PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines

09/22/2021

Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges. The Bio-Manguinhos Institute of Technology on Immunobiologicals […]

Insud Pharma secures “Excellent” rating in the Profarma programme

05/05/2021

It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country It is the second consecutive year that the group has received this rating from the Ministry of Industry The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and […]

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

03/31/2021

The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

03/25/2021

Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]

ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab

02/15/2021

They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix

Spanish group Insud Pharma signs agreement with AstraZeneca to manufacture COVID-19 vaccine candidate

01/20/2021

The plant in Spain’s Castilla-La Mancha region will undertake vial filling and packaging for AZD1222 The company also provides drug substance manufacturing for AZD1222 through their site in Argentina Insud Pharma is at the forefront of Spanish companies in investment in R&D The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of […]

mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine

08/17/2020

mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]

Insud Pharma secures “Excellent” rating in the Profarma programme

07/27/2020

The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019, in recognition of their industrial activity and their commitment to development and innovation. After four consecutive years of obtaining the “Very Good” rating, this plan, an initiative of the Ministry of Industry, […]

Making available free paediatric medicine can accelerate elimination of congenital Chagas disease

04/16/2020

The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children. A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long-standing gap in the treatment of congenital infections of Chagas disease. The donation, by the Mundo Sano Foundation1 and […]

mAbxience inaugurates new monoclonal antibody biosimilar plant in Argentina

02/24/2020

The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Garín, Buenos Aires (Argentina). These drugs are used in the treatment of oncological and autoimmune diseases such as rheumatoid arthritis. With this new plant, the company now has three biosimilar plants, two in Argentina and one in […]